TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA)

Clinical trials for TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) explained in plain language.

Never miss a new study

Get alerted when new TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) trials appear

Sign up with your email to follow new studies for TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Drug could double survival in rare stem cell transplant complication

Disease control Recruiting now

This trial tests the drug eculizumab in adults who develop a severe blood clotting disorder called high-risk transplant-associated thrombotic microangiopathy (TA-TMA) after a stem cell transplant. The condition can cause multiple organ failure and has a poor outlook. The study ai…

Matched conditions: TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA)

Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control

Last updated Jul 19, 2026 00:00 UTC

TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA)

Get alerted when new TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) trials appear

Drug could double survival in rare stem cell transplant complication